Abstract
Background: There is no therapy with proven efficacy to treat cats with feline infectious peritonitis (FIP).
Hypothesis: Feline interferon‐omega (FeIFN‐ω) prolongs survival time and increases quality of life in cats with FIP.
Animals: Thirty‐seven privately owned cats were subjects of this study.
Methods: The study was performed as a placebo‐controlled double‐blind trial. Feline infectious peritonitis was confirmed by histology or immunostaining of feline coronavirus (FCoV) antigen in effusion or tissue macrophages or both. The cats were randomly selected for treatment with either FeIFN‐to or a placebo. All cats received adjunctive treatment with glucocorticoids and antibiotics and passive immunization with Feliserin.
Results: There was no statistically significant difference in the survival time of cats treated with FeIFN‐ω versus placebo or in any other variable evaluated (with the exception of the lymphocyte count). The cats survived between 3 and 200 days (median, 9 days). There was only 1 long‐term survivor (>3 months), and the cat was in the FeIFN‐ω group.
Conclusion and Clinical Relevance: No effect of FeIFN‐ω on survival time or quality of life could be demonstrated in this study.
Keywords: Feline coronavirus (FCoV), Glucocorticoids, Therapy, Treatment
References
- 1. Rohrbach BW, Legendre AM, Baldwin CA, et al. Epidemiology of feline infectious peritonitis among cats examined at veterinary medical teaching hospitals. J Am Vet Med Assoc 2001;218:1111–1115. [DOI] [PubMed] [Google Scholar]
- 2. Pedersen NC. Virologic and immunologic aspects of feline infectious peritonitis virus infection. Adv Exp Med Biol 1987;218:529–550. [DOI] [PubMed] [Google Scholar]
- 3. Pedersen NC, Black JW, Boyle JF, et al. Pathogenic differences between various feline coronavirus isolates. Adv Exp Med Biol 1984;173:365–380. [DOI] [PubMed] [Google Scholar]
- 4. Herrewegh AA, Smeenk I., Horzinek MC, et al. Feline coronavirus type II strains 79–1683 and 79–1146 originate from a double recombination between feline coronavirus type I and canine coronavirus. J Virol 1998;72:4508–4514. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Robison RL, Holzworth J., Gilmore CE. Naturally occurring feline infectious peritonitis: Signs and clinical diagnosis. J Am Vet Med Assoc 1971;158:981–986. [PubMed] [Google Scholar]
- 6. Hartmann K., Binder C., Hirschberger J., et al. Comparison of different tests to diagnose feline infectious peritonitis. J Vet Intern Med 2003;17:781–790. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Tammer R., Evensen O., Lutz H., et al. Immunohistological demonstration of feline infectious peritonitis virus antigen in paraffin‐embedded tissues using feline ascites or murine monoclonal antibodies. Vet Immunol Immunopathol 1995;49:177–182. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Ishida T., Shibanai A., Tanaka S., et al. Use of recombinant feline interferon and glucocorticoid in the treatment of feline infectious peritonitis. J Feline Med Surg 2004;6:107–109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Hartmann K., Kuffer M. Karnofsky's score modified for cats. Eur J Med Res 1998;3:95–98. [PubMed] [Google Scholar]
- 10. Walter JH, Rudolph R. The frequency and pathogenesis of feline infectious peritonitis (FIP) (in German). Dtsch Tierarztl Wochenschr 1989: 96:194–196, 201. [PubMed] [Google Scholar]
- 11. Lutz H., Hauser B., Horzinek MC. Feline infectious peritonitis (FIP): The present state of knowledge. J Small Anim Pract 1986;27:108–116. [Google Scholar]
- 12. McReynolds C., Macy D. Feline infectious peritonitis. Part I. Etiology and diagnosis. Comp Cont Educ Pract Vet 1997; 19:1007–1016. [Google Scholar]
- 13. Ueda Y., Sakurai T., Kasama K., et al. Pharmacokinetic properties of recombinant feline interferon and its stimulatory effect on 2′,5′‐oligoadenylate synthetase activity in the cat. J Vet Med Sci 1993;55:1–6. [DOI] [PubMed] [Google Scholar]
- 14. Weiss RC, Cox NR, Oostrom‐Ram T. Effect of interferon or Propionibacterium acnes on the course of experimentally induced feline infectious peritonitis in specific‐pathogen‐free and random‐source cats. Am J Vet Res 1990;51:726–733. [PubMed] [Google Scholar]
- 15. Hohdatsu T., Okada S., Ishizuka Y., et al. The prevalence of types I and II feline coronavirus infections in cats. J Vet Med Sci 1992;54:557–562. [DOI] [PubMed] [Google Scholar]
- 16. Benetka V., Kubber‐Heiss A., Kolodziejek J., et al. Prevalence of feline coronavirus types I and II in cats with histopathologically verified feline infectious peritonitis. Vet Microbiol 2004;99:31–42. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Brooks BM, Hart CA, Coleman JW. Differential effects of β‐lactams on human IFN‐γ activity. J Antimicrob Chemother 2005;56:1122–1125. [DOI] [PubMed] [Google Scholar]
- 18. Dufour V., Millon L., Faucher J‐F, et al. Effects of a short‐course of amoxicillin/clavulanic acid on systemic and mucosal immunity in healthy adult humans. Int Immunopharmacol 2005; 5:917–928. [DOI] [PubMed] [Google Scholar]
- 19. Kyuwa S., Tagawa Y., Machii K., et al. MHV‐induced fatal peritonitis in mice lacking IFN‐gamma. Adv Exp Med Biol 1998;440:445–450. [DOI] [PubMed] [Google Scholar]
- 20. Bertens AP. Passive and active immunization against feline enteritis and rhinotracheitis in experimental cats (in Dutch). Tijdschr Diergeneeskd 1979;104:107–110. [PubMed] [Google Scholar]
- 21. Weiss RC, Oostrom‐Ram T. Inhibitory effects of ribavirin alone or combined with human alpha interferon on feline infectious peritonitis virus replication in vitro. Vet Microbiol 1989: 20: 255–265. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Bölcskei A., Bilkei G. Langzeitstudie über behandelte FIP‐verdächtige Katzen. Tierärztl Umschau 1995;50:721–728. [Google Scholar]